在报告季度损失并预测全年损失、内幕卖力大和交易量大之后,心脏病治疗药物猛跌14.6%。 Cardiol Therapeutics plunged 14.6% after reporting a quarterly loss and projecting a full-year loss, amid heavy insider selling and high trading volume.

2025年12月2日,心脏病治疗(TSE:CRDL)下降了14.6%,在交易量猛增405%的情况下,跌至1.29 C。 Cardiol Therapeutics (TSE:CRDL) fell 14.6% on December 2, 2025, to close at C$1.29 amid a 405% surge in trading volume. 下降的原因是每股每季度损失0.12科多巴元,分析员预测全年损失0.49科多巴元。 The drop followed a quarterly loss of C($0.12) per share and analysts' projection of a full-year loss of C($0.49). 该公司开发心脏疾病CardiolRxTM,仍然无利可图,市场上限为1.29亿科多巴元,P/E比率为负数,债务与股本比率为1.59,内部销售额为523 093.75美元。 The company, developing CardiolRx™ for heart disease, remains unprofitable with a market cap of C$129 million, a negative P/E ratio, and a debt-to-equity ratio of 1.59. Insider selling of $523,093.75 was also reported.